[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594543":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":162,"collaborators":30,"id":164,"slug":165,"hasResults":166,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":30,"eligibilityCriteria":170,"healthyVolunteers":166,"sex":171,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":30,"studyType":177,"phases":178,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},{"fullName":5,"class":6},"Annexon, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tanruprubart","EXPERIMENTAL","Participants will receive a single 30 mg\u002Fkg intravenous (IV) infusion of tanruprubart on Day 1.",[13],"Drug: Tanruprubart",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Solution for IV infusion.",[9],[20],"ANX005",[22],{"name":23,"affiliation":5,"role":24},"Clinical Trials","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Study Coordinator","CONTACT","1-650-822-5500",null,"clinicaltrials@annexonbio.com",[33,47,56,66,75,80,90,100,110,120,130,140,150],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":30},"St. Joseph's Hospital & Medical Center - Barrow Neurological Institute","RECRUITING","Phoenix","Arizona","85013","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-112.07404,33.44838,{"lat":45,"lon":44},{"facility":48,"status":35,"city":49,"state":37,"zip":50,"country":39,"countryCode":40,"cosmosGeoPoint":51,"geoPoint":55,"contacts":30},"HonorHealth Bob Bové Neuroscience Institute","Scottsdale","85251",{"type":42,"coordinates":52},[53,54],-111.89903,33.50921,{"lat":54,"lon":53},{"facility":57,"status":35,"city":58,"state":59,"zip":60,"country":39,"countryCode":40,"cosmosGeoPoint":61,"geoPoint":65,"contacts":30},"Profound Research LLC","Carlsbad","California","92011",{"type":42,"coordinates":62},[63,64],-117.35059,33.15809,{"lat":64,"lon":63},{"facility":67,"status":35,"city":68,"state":59,"zip":69,"country":39,"countryCode":40,"cosmosGeoPoint":70,"geoPoint":74,"contacts":30},"Children's Hospital of Orange County","Orange","92868",{"type":42,"coordinates":71},[72,73],-117.85311,33.78779,{"lat":73,"lon":72},{"facility":76,"status":35,"city":68,"state":59,"zip":69,"country":39,"countryCode":40,"cosmosGeoPoint":77,"geoPoint":79,"contacts":30},"University of California Irvine",{"type":42,"coordinates":78},[72,73],{"lat":73,"lon":72},{"facility":81,"status":35,"city":82,"state":83,"zip":84,"country":39,"countryCode":40,"cosmosGeoPoint":85,"geoPoint":89,"contacts":30},"University of Colorado Hospital","Aurora","Colorado","80045",{"type":42,"coordinates":86},[87,88],-104.83192,39.72943,{"lat":88,"lon":87},{"facility":91,"status":35,"city":92,"state":93,"zip":94,"country":39,"countryCode":40,"cosmosGeoPoint":95,"geoPoint":99,"contacts":30},"Mayo Clinic Florida","Jacksonville","Florida","32224",{"type":42,"coordinates":96},[97,98],-81.65565,30.33218,{"lat":98,"lon":97},{"facility":101,"status":35,"city":102,"state":103,"zip":104,"country":39,"countryCode":40,"cosmosGeoPoint":105,"geoPoint":109,"contacts":30},"University of Kansas Medical Center","Kansas City","Kansas","66160",{"type":42,"coordinates":106},[107,108],-94.62746,39.11417,{"lat":108,"lon":107},{"facility":111,"status":35,"city":112,"state":113,"zip":114,"country":39,"countryCode":40,"cosmosGeoPoint":115,"geoPoint":119,"contacts":30},"Ochsner LSU Health","Shreveport","Louisiana","71101",{"type":42,"coordinates":116},[117,118],-93.75018,32.52515,{"lat":118,"lon":117},{"facility":121,"status":35,"city":122,"state":123,"zip":124,"country":39,"countryCode":40,"cosmosGeoPoint":125,"geoPoint":129,"contacts":30},"University Massachusetts Chan Medical School","Worcester","Massachusetts","01655",{"type":42,"coordinates":126},[127,128],-71.80229,42.26259,{"lat":128,"lon":127},{"facility":131,"status":35,"city":132,"state":133,"zip":134,"country":39,"countryCode":40,"cosmosGeoPoint":135,"geoPoint":139,"contacts":30},"Henry Ford Health","Detroit","Michigan","48202",{"type":42,"coordinates":136},[137,138],-83.04575,42.33143,{"lat":138,"lon":137},{"facility":141,"status":35,"city":142,"state":143,"zip":144,"country":39,"countryCode":40,"cosmosGeoPoint":145,"geoPoint":149,"contacts":30},"Mayo Rochester","Rochester","Minnesota","55905",{"type":42,"coordinates":146},[147,148],-92.4699,44.02163,{"lat":148,"lon":147},{"facility":151,"status":35,"city":152,"state":153,"zip":154,"country":155,"countryCode":156,"cosmosGeoPoint":157,"geoPoint":161,"contacts":30},"Aarhus University Hospital","Aarhus","Aarhus N","8200","Denmark","DK",{"type":42,"coordinates":158},[159,160],10.21076,56.15674,{"lat":160,"lon":159},{"type":163,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100594543","phase-3-an-open-label-clinical-study-to-evaluate-tanruprubart-also-commonly-known-as-anx005-in-participants-with-guillain-barr-syndrome-forward-study-100594543",false,"NCT07020819","An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)","An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)","Key Inclusion Criteria:\n\n* Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.\n* Onset of GBS-related weakness ≤10 days before start of infusion on Day 1\n* GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1.\n\nKey Exclusion Criteria:\n\n* Previous or intended treatment with either plasma exchange or IV immunoglobulin for GBS.\n* Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes.\n\nOther protocol-defined criteria may apply.","ALL","12 Years","85 Years",{"count":175,"type":176},30,"ESTIMATED","INTERVENTIONAL",[179],"PHASE3","The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.",[182],"Guillain-Barre Syndrome",[182,184,20,9,185],"GBS","FORWARD study","2026-05-27",{"date":188,"type":189},"2026-05-28","ACTUAL",{"date":191,"type":189},"2025-09-12",{"date":193,"type":176},"2028-06-30",{"name":5,"class":6},13]